TechValidate Research on Elsevier PharmaPendium

Introduction

This case study of a medium enterprise pharmaceuticals company is based on an April 2017 survey of Elsevier PharmaPendium customers by TechValidate, a 3rd-party research service. The profiled company asked to have their name blinded to protect their confidentiality.

Challenges

The business challenges that led the profiled company to evaluate and ultimately select Elsevier PharmaPendium are:

• Validating the best animal models to use and predict how results translate to the clinic
• Reducing the number of preclinical studies that are required by citing relevant preclinical studies

Use Case

The surveyed company uses PharmaPendium on a project-basis and has >5 drugs in the pipeline

Results

The surveyed company rated their level of agreement with the following statements about PharmaPendium:

• Is the only online source of text searchable FDA and EMA drug approval documents: partially agree
• Facilitates comparative analyses across drugs, targets, adverse effects and indications: partially agree
• Provides important insights that impact the success of a project: partially agree
• Enables them to find actionable information much faster than other methods: partially agree
• Helps to address bottleneck / urgent issues that arise during drug development: partially agree
• Provides translational insights that are critical for my work: partially agree

• The company uses the data in PharmaPendium for their work in the following ways:
  • To better inform drug candidate selection by looking at comparative preclinical and clinical safety, deliverability and/or efficacy data
  • To better design preclinical studies that provide greater insight into potential clinical safety risk and/or clinical outcome

The survey respondents recommend continuing to continue subscribe to PharmaPendium.

Introduction

This case study of Teva is based on a May 2017 survey of Elsevier PharmaPendium customers by TechValidate, a 3rd-party research service.

Challenges

The business challenges that led Teva to evaluate and ultimately select Elsevier PharmaPendium:

• Reduce the number of preclinical studies that are required by citing relevant preclinical studies
• Have more confidence in go/no-go drug development decisions/recommendations
• Improve the speed and success of regulatory submissions

Use Case

• Uses PharmaPendium weekly.

• Teva has:
  • >5 drugs in the pipeline
  • A focus on generic drugs
  • An involvement in regulatory submissions
  • A focus on performing clinical trials on drugs in development

Results

Teva uses the data in PharmaPendium for their work in the following ways:

• To better inform drug candidate selection by looking at comparative preclinical and clinical safety, deliverability and/or efficacy data
• To design better clinical trials that will optimize benefit:risk ratio for their drug candidate
• To better understand safety risks related to drug-drug interactions, off-target effects and/or polypharmacy

• Teva would spend over 50% more time collecting the equivalent information without access to PharmaPendium.

• Survey respondents recommend to continue subscribing to PharmaPendium.